Navigation Links
TOPICA Names Mark W. Davis Vice President of Clinical Development
Date:2/18/2010

PALO ALTO, Calif., Feb. 18 /PRNewswire/ -- TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced the appointment of Mark W. Davis as Vice President of Clinical Development.  In this position, Mr. Davis will lead TOPICA's clinical development activities for luliconazole, its lead product candidate, for the treatment of onychomycosis (nail and nail bed fungal infections) and tinea pedis (athlete's foot).  The company expects to initiate a Phase 1/2a trial of luliconazole in the U.S. for onychomycosis during the first quarter of 2010 and to advance luliconazole into a Phase 3 clinical development program for tinea pedis this year.  

"Mark Davis is a very experienced clinical development leader with a solid background in dermatology," said Greg Vontz, president and CEO of TOPICA.  "Mark's understanding of the clinical development process, as well as his long-standing relationship with the FDA's Dermatology Division is vital to TOPICA's success and he will play a major role in our preparation for commercialization of luliconazole."

"Based on luliconazole's strong clinical profile, clinical development programs and previous approval in Japan, as well as TOPICA's robust Phase 2 study in tinea pedis, I believe the compound is poised for terrific success," said Mr. Davis.  "I will be working diligently to advance all of the clinical development programs for luliconazole with a specific near-term focus on leading development efforts in onychomycosis where this anti-fungal therapy could become the first truly effective and safe topical therapy for patients."

Mr. Davis has more than 27 years of experience in the biotechnology, pharmaceutical and medical device industry.  Prior
'/>"/>

SOURCE TOPICA Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TOPICA Announces Participation in BioPartnering North America
2. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
3. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. TOPICA Announces Positive Phase 2 Clinical Results for Luliconazole, a Potent Topical Antifungal
5. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
6. ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)
7. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
8. Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain
9. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
10. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
11. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015   Decision Resources ... differences in dialysis patient management in the U.S. ... submitted by U.S. and EU5 nephrologists from approximately ... binders are the most commonly used renal medications ... iron differs considerably between the two regions.      ...
(Date:7/7/2015)... , July 7, 2015 The ... USD 1,197.7 million by 2020, growing at an estimated CAGR ... study by Grand View Research, Inc. Introduction of innovative technologies ... with growing awareness levels pertaining to the advantages of breast ... next six years. In addition, presence of untapped growth opportunities ...
(Date:7/7/2015)... , July 7, 2015 EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering of 32,000,000 units. Each unit ... Series A warrant to purchase one share of common ... Investors whose purchase of units in the offering would ...
Breaking Medicine Technology:Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
... SAN RAFAEL, Calif. , Aug. 4 To ... companies have selected New Momentum, the leading SaaS-based anti-counterfeiting solution.  Both ... and shut down violators, their New Momentum solution will play a ... , , ...
... Aug. 4 Cytel Inc., premier provider of adaptive clinical trial ... software package for adaptive dose-finding studies based on frequentist or Bayesian methods. , ... The FDA,s recently issued adaptive trial guidelines ... level.  , , , ...
Cached Medicine Technology:Two More Global Pharmaceutical Companies Choose New Momentum to Stop Counterfeits 2Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies 2Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies 3
(Date:7/7/2015)... ... 07, 2015 , ... This week Northeast Nebraska Imaging, Norfolk’s ... The website’s goal is to provide patients with detailed information about the various ... appointments online. , Part of the center’s rebranding efforts, the website was designed ...
(Date:7/7/2015)... ... July 07, 2015 , ... The United States Centers ... Committee of Massachusetts , and the Multicultural AIDS Coalition $3.78 million for ... who have sex with men (MSM) and transgender women, the groups at highest ...
(Date:7/7/2015)... ... ... Quadrino Law Group is pleased to announce the relocation of the firm's headquarters to ... is a state of the art building, located with easy access to New York ... said, "We are pleased to service our clients from such a premier location and ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... global provider of advanced delivery technologies and development solutions for drugs, biologics ... licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) ...
(Date:7/7/2015)... R.I. (PRWEB) , ... July 07, 2015 , ... Summer ... the proper precautions, however, so Amica Insurance is sharing some safety tips. , Jean ... sports and gardening: , Leisure activities/sports, , Start slowly. Going ...
Breaking Medicine News(10 mins):Health News:Northeast Nebraska Imaging Launches New Patient Friendly Website 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 3Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Amica Insurance Has 7 Summer Safety Tips 2
... Media Alert ... Seattle, WA (Vocus) October ... bringing its popular Hot Topics in Plastic Surgery panel directly to journalists during a Hot ... questions on emerging procedures, trends, and new technologies while engaging in conversation with the experts. ...
... Corporation (NYSE: PER ) announced today that it has ... in which the two companies intend to work together to ... in China. , "Perot Systems and China Telecom ... e-health platform and IT services that support the advancement of ...
... Multicenter study in 30 children and young adults shows ... Children born with certain heart defects have impaired blood ... leading to the lungs, requiring implanted devices (known as ... these conduits fail over time, and children typically face ...
... for America,s Health (TFAH) released a new report ... climate change plan that includes a public health response. This ... from natural disasters, pollution, and infectious diseases as temperatures and ... Up: Climate Change and the Public,s Health report examines ...
... topic of particle or ion therapy radiation with heavy ... of 2009 in Heidelberg. Well over 600 international participants, especially ... Hall for the annual meeting of the "Particle Therapy Cooperative ... therapy, medical physics and oncology. "There have been ...
... Clinic study suggests that video capsule endoscopy ... intestinal disease, is safe for patients with heart devices. ... shown to interfere with implanted heart devices, including pacemakers ... speculate that capsule endoscopy could similarly cause heart devices ...
Cached Medicine News:Health News:Plastic Surgeons to Discuss Cleavage Rejuvenation, Do-It-Yourself Lasers and Other Hot Topics with the Media 2Health News:Perot Systems Announces Strategic Alliance With China Telecom 2Health News:Perot Systems Announces Strategic Alliance With China Telecom 3Health News:Catheter-Delivered Valve May Help People With Heart Defects Avoid Multiple Surgeries 2Health News:Catheter-Delivered Valve May Help People With Heart Defects Avoid Multiple Surgeries 3Health News:Catheter-Delivered Valve May Help People With Heart Defects Avoid Multiple Surgeries 4Health News:Only Five States Have Plans to Address the Health Impact of Climate Change, New Report Finds 2Health News:Only Five States Have Plans to Address the Health Impact of Climate Change, New Report Finds 3Health News:Only Five States Have Plans to Address the Health Impact of Climate Change, New Report Finds 4Health News:The largest congress worldwide on ion therapy in Heidelberg 2Health News:Mayo Clinic study shows people with heart devices can 'digest' advanced diagnostic technology safely 2Health News:Mayo Clinic study shows people with heart devices can 'digest' advanced diagnostic technology safely 3
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Legionella provides rapid, accurate results that aid in the presumptive diagnosis of Legionella infection (Legionnaires' Disease)....
... The Trinity Biotech Captia™ ... Assay (ELISA) is intended for ... antibodies (IgG and IgM) to ... in serum from patients with ...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
Medicine Products: